Objective:To observe the therapeutic effect of Baijinwan aqueous solvent in the treatment of hyperlipidemic mice. Methods48 mice were randomly divided into the control group, model group, Baijinwan group with high and low dose (6.4 g·kg-1,1.6 g·kg-1), Xuezhikang group (0.16 g·kg-1) and statin group (0.0026 g·kg-1), and 8 mice in each group. Except the control group, the rest groups were given high fat diet to establish the hyperlipidemia model. Four weeks later, mice in different groups were treated with corresponding drugs by means of intragastric administration,with a course of 15 days. The body weight,liver index,serum total cholesterol (TC) ,triglyceride (TG) ,low-density lipoprotein cholesterol(LDL-C) ,high-density lipoprotein cholesterol (HDL-C) ,the liver superoxide dismutase (SOD)and malondialdehyde (MDA) of mice were detected and compared.  Results:Compared with the control group, body weight and liver index of the model group significantly increased (P<0.05). Compared with the model group, body weight and liver index of Baijinwan groups significantly decreased (P<0.05); TG of Baijinwan group with high-and low-dose significantly decreased (P<0.05), LDL of Baijinwan group with low-dose significantly decreased (P<0.05), HDL of Baijinwan group with high-and low-dose significantly increased. (P<0.05); MDA in liver homogenates of Baijinwan group with low-dose significantly decreased. (P<0.05), MDA in liver homogenates of Baijinwan group with high-dose significantly decreased (P<0.01). Compared with the model group, the activity of SOD in liver homogenates of atorvastatin group and Baijinwan group with low-dose increased significantly (P<0.05).  Conclusion:Baijinwan aqueous solvents could significantly reduce body weight and liver index of hyperlipidemic mice,which regulated lipid metabolism by reducing TG,LDL-C and increasing HDL-C. Meanwhile ,it decreased MDA and increased the activity of SOD in liver.